L'Oréal S.A. (OR)
Euronext Paris · Clichy, France · Founded 1909 · CEO Nicolas Hieronimus
Valuation summary
$279.50 fair value versus $471.47 in the market, a difference of -40.7%. Rated Sell.
| Fair value per share | $279.50 |
| Current share price | $471.47 |
| Upside / downside | -40.7% |
| Bear case | $184.27 |
| Bull case | $417.40 |
| Discount rate (WACC) | 8.6% |
| Terminal growth | 2.40% |
| Market capitalisation | $252B |
| EV / Sales | 5.4x |
About L'Oréal S.A.
Founded in 1909 by chemist Eugène Schueller, who invented a safe synthetic hair dye. Nicolas Hieronimus is CEO; the Bettencourt Meyers family and Nestlé remain large shareholders. L'Oréal is the largest beauty company in the world across four divisions: Luxe with Lancôme, Yves Saint Laurent Beauté and Armani; Consumer Products with Maybelline, Garnier and L'Oréal Paris; Dermatological Beauty with La Roche-Posay, CeraVe and Vichy, the fastest-growing division; and Professional Products for salons. Prices quoted in euros.
Investment case
- Dermatological beauty, particularly CeraVe and La Roche-Posay, is growing fast and is recommended by dermatologists, which is powerful marketing.
- Beauty has proven remarkably resilient in downturns — the so-called lipstick effect is real.
- Research and development spending is far higher than peers, producing genuine formulation advantages.
Key risks
- Chinese demand for premium beauty has been weak and China was the main growth engine.
- Competition from social-media-native brands is intense in colour cosmetics.
- The valuation has historically been high and leaves little room for growth disappointment.
Recent developments
- 2026-10-22 · Q3 sales beat forecasts as premium haircare and dermatological beauty accelerate; nine-month sales up 7.7% source
- 2026-09-23 · HSBC reiterated Buy with a EUR450 target while Deutsche Bank kept Sell at EUR340, citing warning signs in Chinese cosmetics imports source
Revenue by segment
| Consumer Products | 37% |
| L'Oréal Luxe | 34% |
| Dermatological Beauty | 17% |
| Professional Products | 12% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $49.4B | $7.6B |
| Year 2 | $51.8B | $8.2B |
| Year 3 | $54.4B | $8.8B |
| Year 4 | $56.6B | $9.4B |
| Year 5 | $58.8B | $10.0B |
What the street says
Viewed as the highest-quality beauty asset globally. The China recovery timing is the central uncertainty.
Comparable companies: MC · PG · SBUX · NESN · HD · TJX · PEP · KO
Open the interactive model, price chart and sensitivity grid →